Literature DB >> 29966110

Optimised dosing of vancomycin in critically ill Indigenous Australian patients with severe sepsis.

D Tsai1, P C Stewart, S Hewagama2, S Krishnaswamy3, S C Wallis4, J Lipman5, J A Roberts6.   

Abstract

Vancomycin is a commonly used antibiotic due to the high burden of methicillin-resistant <i>Staphylococcus aureus</i> infections. This study aimed to describe the pharmacokinetics (PK) of vancomycin in Australian Indigenous patients with severe sepsis, and advise an optimal dosing strategy. A population PK study was conducted in a remote Australian intensive care unit (ICU). Serial plasma samples were collected over one to two dosing intervals and assayed by validated chromatography. Concentration-time data collected were analysed using Pmetrics® software. The final population PK model was then used for Monte Carlo dosing simulations to determine optimal loading and intermittent maintenance doses. Fifteen Indigenous subjects were included for analysis with a median (interquartile range, IQR) age, weight and creatinine clearance (CrCL) of 43 (34-46) years, 73 (66-104) kg and 99 (56-139) ml/minute respectively. A two-compartment model described the data adequately. Vancomycin clearance (CL) and volume of distribution of the central compartment (Vc) were described by CrCL and patient weight respectively. Median (IQR) CL, Vc, distribution rate constants from central to peripheral, and from peripheral to central compartments were 4.6 (3.8-5.6) litres per hour, 25.4 (16.1-31.3) litres, 0.46 (0.28-0.52)/hour and 0.25 (0.12-0.37)/hour respectively. No significant interethnic PK differences were observed in comparison to published data. Therapeutic loading doses were significantly dependent on both weight and CrCL, whereas maintenance doses were dependent on CrCL. In the absence of severe renal impairment, initiation of maintenance dose eight hours post-loading dose achieved higher probability of target attainment at 24 hours. This is the first report of vancomycin PK in this patient group.

Entities:  

Keywords:  Indigenous; dosing; pharmacokinetics; severe sepsis; vancomycin

Mesh:

Substances:

Year:  2018        PMID: 29966110     DOI: 10.1177/0310057X1804600405

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  5 in total

1.  Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach.

Authors:  Qingxia Liu; Huiping Huang; Baohua Xu; Dandan Li; Maobai Liu; Imam H Shaik; Xuemei Wu
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

2.  Relationship Between Mean Vancomycin Trough Concentration and Mortality in Critically Ill Patients: A Multicenter Retrospective Study.

Authors:  Yanli Hou; Jiajia Ren; Jiamei Li; Xuting Jin; Ya Gao; Ruohan Li; Jingjing Zhang; Xiaochuang Wang; Xinyu Li; Gang Wang
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

3.  An evaluation on the association of vancomycin trough concentration with mortality in critically ill patients: A multicenter retrospective study.

Authors:  Jiajia Ren; Yanli Hou; Jiamei Li; Ya Gao; Ruohan Li; Xuting Jin; Jingjing Zhang; Xiaochuang Wang; Gang Wang
Journal:  Clin Transl Sci       Date:  2021-04-09       Impact factor: 4.689

Review 4.  Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Kazuaki Matsumoto; Kazutaka Oda; Kensuke Shoji; Yuki Hanai; Yoshiko Takahashi; Satoshi Fujii; Yukihiro Hamada; Toshimi Kimura; Toshihiko Mayumi; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue
Journal:  Pharmaceutics       Date:  2022-02-23       Impact factor: 6.321

5.  Why we should sample sparsely and aim for a higher target: Lessons from model-based therapeutic drug monitoring of vancomycin in intensive care patients.

Authors:  Tingjie Guo; Reinier M van Hest; Lucas M Fleuren; Luca F Roggeveen; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Johan G C van Hasselt; Paul W G Elbers
Journal:  Br J Clin Pharmacol       Date:  2020-08-17       Impact factor: 3.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.